Management of bleeding complications in the anticoagulated patient.

As new anticoagulants become available, and the number of anticoagulated patients continues to rise, it is necessary to know how to deal with associated bleeding complications. In this review, reversal strategies for traditional anticoagulants (warfarin and heparin) as well as newer anticoagulants are described. Prothrombin complex concentrates (PPCs) can be used to reverse vitamin K antagonists (VKA), and plasma may be used where they are not available. Recombinant activated factor VII (rFVIIa) may be useful to reverse pentasaccharide anticoagulants. 1-Desamino-8-D-arginine vasopressin (DDAVP), cryoprecipitate, PCCs, and dialysis may help to reverse direct thrombin inhibitors, while rFVIIa seems to be ineffective. The effect of direct factor Xa inhibitors may be reversed by PCCs, FVIIa, or factor Xa concentrates.

[1]  B. Nieswandt,et al.  Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke , 2011, Journal of thrombosis and haemostasis : JTH.

[2]  M. Collecutt,et al.  Prothrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation , 2011, Internal medicine journal.

[3]  M. Makris,et al.  Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal? , 2011, Blood transfusion = Trasfusione del sangue.

[4]  W. Ageno,et al.  Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. , 2011, Blood transfusion = Trasfusione del sangue.

[5]  G. Raskob,et al.  Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis , 2011, Journal of thrombosis and haemostasis : JTH.

[6]  Donald R. Lynch.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[7]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[8]  G. Raskob,et al.  Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. , 2010, The New England journal of medicine.

[9]  S. Yusuf,et al.  Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation , 2010, Circulation.

[10]  M. Levi,et al.  Safety of recombinant activated factor VII in randomized clinical trials. , 2010, The New England journal of medicine.

[11]  M. Prins,et al.  Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. , 2010, The Cochrane database of systematic reviews.

[12]  G. Pernod,et al.  French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). , 2010, Thrombosis research.

[13]  K. Rathgen,et al.  Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate , 2010, Clinical pharmacokinetics.

[14]  G. Raskob,et al.  Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial , 2010, The Lancet.

[15]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[16]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[17]  G. Raskob,et al.  Apixaban or enoxaparin for thromboprophylaxis after knee replacement. , 2009, The New England journal of medicine.

[18]  J. Harenberg.  Development of idraparinux and idrabiotaparinux for anticoagulant therapy , 2009, Thrombosis and Haemostasis.

[19]  M. Crowther,et al.  Suboptimal effect of a three‐factor prothrombin complex concentrate (Profilnine‐SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose , 2009, Transfusion.

[20]  M. Gent,et al.  Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial , 2009, The Lancet.

[21]  E. Perzborn,et al.  Prothrombin Complex Concentrate Reverses the Effects of High-Dose Rivaroxaban in Rats , 2009 .

[22]  B. Ratner,et al.  Molecularly designed surfaces for blood deheparinization using an immobilized heparin-binding peptide. , 2009, Journal of biomedical materials research. Part A.

[23]  D. Phillips,et al.  Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors. , 2008 .

[24]  A. Gruber,et al.  Potential of Activated Prothrombin Complex Concentrate and Activated Factor VII to Reverse the Anticoagulant Effects of Rivaroxaban in Primates , 2008 .

[25]  J. Herbert,et al.  Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy , 2008, Journal of thrombosis and haemostasis : JTH.

[26]  M. Nybo,et al.  Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. , 2008, Basic & clinical pharmacology & toxicology.

[27]  Bengt I Eriksson,et al.  Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial , 2008, The Lancet.

[28]  P. Johansson,et al.  Off‐label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials , 2008, Vox sanguinis.

[29]  W. Ageno,et al.  Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. , 2008, The New England journal of medicine.

[30]  B. Eriksson,et al.  Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. , 2008, The New England journal of medicine.

[31]  J. Hirsh,et al.  Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[32]  R. Beyth,et al.  Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[33]  A. Lincoff,et al.  Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[34]  Mark Crowther,et al.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[35]  M. Crowther,et al.  Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. , 2008, Blood.

[36]  A. Greinacher,et al.  The direct thrombin inhibitor hirudin , 2008, Thrombosis and Haemostasis.

[37]  S. Knaub,et al.  Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial , 2008, Journal of thrombosis and haemostasis : JTH.

[38]  S. Lévy,et al.  Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial , 2008, The Lancet.

[39]  F. Dentali,et al.  Management of excessive anticoagulant effect due to vitamin K antagonists. , 2008, Hematology. American Society of Hematology. Education Program.

[40]  M. Crowther,et al.  What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008. , 2008, Hematology. American Society of Hematology. Education Program.

[41]  R. Beyth,et al.  Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[42]  G. Young,et al.  Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[43]  Y. Arabi,et al.  Recombinant Activated Factor VII Treatment of Retroperitoneal Hematoma in a Patient with Renal Failure Receiving Enoxaparin and Clopidogrel , 2007, Pharmacotherapy.

[44]  C. White,et al.  Use of protamine to rapidly reverse anticoagulant effect of unfractionated heparin in patients undergoing percutaneous coronary intervention. , 2007, Connecticut medicine.

[45]  D. Benhamou,et al.  Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage , 2007, Intensive Care Medicine.

[46]  S. Schulman,et al.  Anticoagulants and their reversal. , 2007, Transfusion medicine reviews.

[47]  E. Wijdicks,et al.  Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP , 2006, Neurology.

[48]  P. Morange,et al.  Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. , 2006, Blood.

[49]  C. Kessler,et al.  Reversal of low‐molecular‐weight heparin‐induced bleeding in patients with pre‐existing hypercoagulable states with human recombinant activated factor VII concentrate , 2006, American journal of hematology.

[50]  T. Albertson,et al.  Reversal of Elevated International Normalized Ratios and Bleeding with Low‐Dose Recombinant Activated Factor VII in Patients Receiving Warfarin , 2006, Pharmacotherapy.

[51]  K. Friedman,et al.  Urgent reversal of warfarin with prothrombin complex concentrate , 2006, Journal of thrombosis and haemostasis : JTH.

[52]  W. S. Akers,et al.  Recombinant Factor VIIa for Refractory Bleeding After Cardiac Surgery Secondary to Anticoagulation with the Direct Thrombin Inhibitor Lepirudin , 2006, Pharmacotherapy.

[53]  J. Crawford,et al.  Prothrombinex use for the reversal of warfarin: is fresh frozen plasma needed? , 2006, The Medical journal of Australia.

[54]  H G Watson,et al.  Guidelines on oral anticoagulation (warfarin): third edition – 2005 update , 2006, British journal of haematology.

[55]  M. Braun,et al.  Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. , 2006, JAMA.

[56]  P. Strengers,et al.  Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. , 2006, Thrombosis research.

[57]  J. Douketis,et al.  Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. , 2006, JAMA.

[58]  T. Lecompte,et al.  Lepirudin: is the approved dosing schedule too high? , 2005, Journal of thrombosis and haemostasis : JTH.

[59]  A. Greinacher,et al.  Lepirudin in patients with heparin‐induced thrombocytopenia – results of the third prospective study (HAT‐3) and a combined analysis of HAT‐1, HAT‐2, and HAT‐3 , 2005, Journal of thrombosis and haemostasis : JTH.

[60]  N. Carlson,et al.  Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa. , 2005, The American journal of medicine.

[61]  R. Slappendel,et al.  Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. , 2005, The Netherlands journal of medicine.

[62]  M. Kamien.  Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis , 2005, The Medical journal of Australia.

[63]  D. Brody,et al.  Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage , 2005, Neurocritical care.

[64]  T. Brott,et al.  Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. , 2004, Mayo Clinic proceedings.

[65]  B. Kanna,et al.  Enoxaparin vs unfractionated heparin in acute coronary syndrome. , 2004, JAMA.

[66]  H. White,et al.  Safety and efficacy of enoxaparin vs. unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes. who receive tirofiban and aspirin ☆ , 2004 .

[67]  R. Califf,et al.  Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. , 2004, JAMA.

[68]  G. Dehmer,et al.  Recombinant platelet factor 4 for heparin neutralization. , 2004, Seminars in thrombosis and hemostasis.

[69]  M. Wolzt,et al.  Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers , 2004, Thrombosis and Haemostasis.

[70]  J. D. San Antonio,et al.  Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo. , 2004, Blood.

[71]  F. Depasse,et al.  Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood , 2004, Thrombosis and Haemostasis.

[72]  S. Malherbe,et al.  Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. , 2004, Anesthesiology.

[73]  Persist investigators.  A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation , 2004, Journal of thrombosis and haemostasis : JTH.

[74]  M. Prins,et al.  Fixed dose subcutaneous low molecular weight heparins versus adjusted dose infractionated heparin for venous thromboembolism [Cochrane review] , 2004 .

[75]  Kyung W. Park.  Protamine and Protamine Reactions , 2004, International anesthesiology clinics.

[76]  R. Zimlichman,,et al.  Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. , 2004, Thrombosis research.

[77]  H. Halkin,et al.  Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. , 2003, Archives of internal medicine.

[78]  P. D. de Groot,et al.  Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux , 2003, Journal of thrombosis and haemostasis : JTH.

[79]  J. Kelton,et al.  Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. , 2003, Archives of internal medicine.

[80]  R. Peters,et al.  Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers , 2003 .

[81]  J. C. Sørensen,et al.  Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[82]  M. Tarantino,et al.  The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. , 2003, Journal of neurosurgery.

[83]  H. Ng,et al.  Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin , 2003, Annals of Hematology.

[84]  J. Douketis,et al.  Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin k in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial☆ , 2003 .

[85]  C. Kessler,et al.  Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate , 2002, Annals of Internal Medicine.

[86]  David A Fitzmaurice,et al.  ABC of antithrombotic therapy : Bleeding risks of , 2002 .

[87]  G. Volcheck,et al.  The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[88]  H. Naritomi,et al.  Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. , 2002, Thrombosis research.

[89]  J. Douketis,et al.  Oral Vitamin K Lowers the International Normalized Ratio More Rapidly Than Subcutaneous Vitamin K in the Treatment of Warfarin-Associated Coagulopathy , 2002, Annals of Internal Medicine.

[90]  M. Crowther,et al.  Reversing anticoagulants both old and new. , 2002, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[91]  S. Kitchen,et al.  Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients , 2002, British journal of haematology.

[92]  R. Califf,et al.  Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data , 2002, The Lancet.

[93]  A. Mitchell,et al.  Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. , 2002, JAMA.

[94]  P. Monagle,et al.  Mechanisms responsible for the failure of protamine 
to inactivate low‐molecular‐weight heparin , 2002, British journal of haematology.

[95]  J. Necciari,et al.  The Pharmacokinetics of Fondaparinux Sodium in Healthy Volunteers , 2002, Clinical pharmacokinetics.

[96]  L. Delbressine,et al.  Fondaparinux Sodium Is Not Metabolised in Mammalian Liver Fractions and Does Not Inhibit Cytochrome P450-Mediated Metabolism of Concomitant Drugs , 2002, Clinical pharmacokinetics.

[97]  T. Baglin,et al.  Beriplex P/N reverses severe warfarin‐induced overanticoagulation immediately and completely in patients presenting with major bleeding , 2001, British journal of haematology.

[98]  M. Makris,et al.  The management of coumarin‐induced over‐anticoagulation , 2001 .

[99]  J. Bartholomew,et al.  Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia , 2001, Circulation.

[100]  J. D. San Antonio,et al.  Novel Design of Peptides to Reverse the Anticoagulant Activities of Heparin and other Glycosaminoglycans , 2001, Thrombosis and Haemostasis.

[101]  S. Carlsson,et al.  Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. , 2001, Thrombosis research.

[102]  M. Makris,et al.  The management of coumarin-induced over-anticoagulation Annotation. , 2001, British journal of haematology.

[103]  A. Greinacher,et al.  Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. , 2000, Blood.

[104]  D. Singer,et al.  Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. , 2000, Archives of internal medicine.

[105]  R. Tait,et al.  A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over‐warfarinization , 2000, British journal of haematology.

[106]  J. Douketis,et al.  A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. , 2000, Archives of internal medicine.

[107]  Marshall A. Lichtman,et al.  Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961 , 2000 .

[108]  P O Byrne,et al.  Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. , 2000, British journal of neurosurgery.

[109]  R. Kumar,et al.  Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. , 1999, Archives of internal medicine.

[110]  A. Schmaier,et al.  Use of factor IX complex in warfarin-related intracranial hemorrhage. , 1999, Neurosurgery.

[111]  T. Hastie,et al.  Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis , 1999, Annals of Internal Medicine.

[112]  Robert H. Nee,et al.  Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. , 1999, The American journal of cardiology.

[113]  M. Gould,et al.  Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. , 1999, Annals of internal medicine.

[114]  D. Perry,et al.  Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. , 1998, Clinical and laboratory haematology.

[115]  V. Yang,et al.  Poly-L-lysine amplification of protamine immobilization and heparin adsorption. , 1998, Journal of biomedical materials research.

[116]  G. Dickneite,et al.  Development of an Anti-Bleeding Agent for Recombinant Hirudin Induced Skin Bleeding in the Pig , 1998, Thrombosis and Haemostasis.

[117]  B. Larke,et al.  Guidelines for red blood cell and plasma transfusion for adults and children. , 1997, The International journal of risk & safety in medicine.

[118]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[119]  F. Rosendaal,et al.  Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy , 1997, Thrombosis and Haemostasis.

[120]  M. Fisher,et al.  Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humans. , 1996, Circulation.

[121]  E. Antman.  Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.

[122]  V. Marder,et al.  DDAVP Reduces Bleeding during Continued Hirudin Administration in the Rabbit , 1996, Thrombosis and Haemostasis.

[123]  Y. Byun,et al.  Optimization and assessment of the in vivo efficacy of a heparin removing bio-reactor using mathematical modeling. , 1996, ASAIO journal.

[124]  M. Simoons.  A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.

[125]  A. Jessel,et al.  Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. , 1995, Haemostasis.

[126]  L. Wilkins.  Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. , 1994, Circulation.

[127]  E. Antman.  Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. , 1994, Circulation.

[128]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[129]  B. Norrving,et al.  Emergency Reversal of Anticoagulation After Intracerebral Hemorrhage , 1992, Stroke.

[130]  N. Adkinson,et al.  Allergy to protamine , 1991, Clinical reviews in allergy.

[131]  S. Ibbotson,et al.  The Influence of Infusions of 1-Desamino-8-D-Arginine vasopressin (DDAVP) In Vivo on the Anticoaguhht Effect of Recombinant Hirudin (CGP39393) In Vitro , 1991, Thrombosis and Haemostasis.

[132]  J. Weiler,et al.  A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. , 1990, The Journal of allergy and clinical immunology.

[133]  L Goldman,et al.  Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. , 1989, The American journal of medicine.

[134]  C. Hirshman,et al.  Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. , 1989, The New England journal of medicine.

[135]  J. Hirsh,et al.  Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. , 1986, Thrombosis research.

[136]  A. Morabia.  HEPARIN DOSES AND MAJOR BLEEDINGS , 1986, The Lancet.

[137]  T. Ryan,et al.  Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization. , 1984, Circulation.

[138]  Caplan Sn,et al.  Letter: Reactive hypoglycemia: fact or fiction? , 1976 .

[139]  S. Caplan,et al.  Letter: Protamine sulfate and fish allergy. , 1976, The New England journal of medicine.

[140]  S. Lewis,et al.  British Committee for Standards in Haematology , 1969 .